Shanghai Race announced that Guangxi Laishi Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, an application for registration and marketing license for domestic production of human blood albumin was accepted by the State Drug Administration on November 3, 2026, with acceptance number CXSS2600185. The drug is subject to subsequent review and approval, and can only be manufactured and sold after approval. There is uncertainty about the registration completion time, approval results, and post-marketing sales.

Shanghai Race announced that Guangxi Laishi Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, an application for registration and marketing license for domestic production of human blood albumin was accepted by the State Drug Administration on November 3, 2026, with acceptance number CXSS2600185. The drug is subject to subsequent review and approval, and can only be manufactured and sold after approval. There is uncertainty about the registration completion time, approval results, and post-marketing sales.